Lung cancer combo trial halted after just 4 patients
NCT ID NCT05215951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meaningful conclusions can be drawn. The goal was to see if the combination could shrink tumors and delay cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
osimertinib (Tagrisso) plus platinum and pemetrexed chemotherapy
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced lung cancer that has rare EGFR mutations.
What could go wrong
This was a very small, early-phase study that was terminated early, so results are limited. The combination may not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Chengdu, 610041, China
-
Research Site
Harbin, 150049, China
-
Research Site
Mianyang, 621000, China
-
Research Site
Nanchong, 637000, China
-
Research Site
Yibin, 644000, China
-
Research Site
Zhengzhou, 450000, China